HaplnScience, Inc. recently recruited Dr. Jangsoo Yoon, a former clinical trial leader of Boehringer Ingelheim (BI)  as Chief Medical Officer (CMO). Dr. Yoon is an expert in clinical trials, leading clinical trials in Korean and Japan BI for years. HaplnScience plans to submit phase I IND application to US FDA for the leading project, and Dr. Yoon will lead clinical programs of HaplnScience pipeline.